| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07:42 | RBC downgrades Equifax stock rating on mortgage weakness concerns | ||
| 07:30 | SBFC Finance Q2 FY27 slides: 27% growth amid market caution | ||
| 07:30 | Jupiter Hospital Q2FY27 slides: revenue rises, expansion weighs on profit | ||
| 07:30 | Gerdes downgrades Range Resources stock rating to neutral on valuation | ||
| 07:30 | Jefferies upgrades Orion stock on Nubeqa patent outlook | ||
| 07:30 | JPMorgan initiates Accelevation stock with overweight rating | ||
| 06:06 | Unicommerce Q2 FY27 slides: 15% growth amid strategic AI investments | ||
| 02:06 | Ramelius Q1 FY27 slides: cash surges to A$768M as growth ramps | ||
| 02:06 | 6K Additive Q3 2026 slides: record backlog drives expansion plans | ||
| 02:06 | Greatland Q1 FY27 slides: production beats, Havieron underway | ||
| 00:42 | Mach7 Q1 FY27 slides: cash flow positive, Flamingo launch ahead | ||
| 00:42 | Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data | ||
| 00:30 | Oppenheimer reiterates Amgen stock rating on cancer drug data | ||
| 00:30 | Stifel raises Hinge Health stock price target on app growth rebound | ||
| 00:30 | Nokia stock rating upgraded to Reduce by IndeRes on strong Q3 results | ||
| 00:30 | IndeRes upgrades Nokia stock rating on strong Q3 results | ||
| 00:30 | RBC reiterates Intel stock rating on AI demand, foundry progress | ||
| So | Jefferies upgrades Dr. Reddy's stock rating on margin outlook | ||
| So | ArriVent reports phase 1 data for cancer drug ARR-217 | ||
| So | Amarin's icosapent ethyl shows survival benefit in cancer trial | ||
| So | NovaBridge reports phase 1b data for gastric cancer drug | ||
| So | Genmab reports phase 2 trial data for colorectal cancer drug | ||
| So | Brookfield to open Qatar office as it expands Middle East operations | ||
| So | Xencor reports phase 1 data for cancer drug XmAb819 | ||
| So | BioNTech, Bristol Myers report lung cancer trial data |